Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | HPGD | P15428 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583954 | 0.85 | STAT3 (0.43) | STAT3TSHRMAPK1ALDH1A1TOP1 | |
| SCHEMBL2840255 | 0.82 | GSK3B (0.37) | STAT3TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL2840258 | 0.82 | GSK3B (0.37) | STAT3TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL584783 | 0.82 | STAT3 (0.45) | STAT3TSHRMAPK1ALDH1A1TOP1 | |
| Hydrochloric Acid SCHEMBL584782 | 0.81 | STAT3 (0.44) | STAT3TSHRMAPK1ALDH1A1TOP1 | |
| SCHEMBL585458 | 0.79 | STAT3 (0.39) | STAT3TSHRMAPK1ALDH1A1TOP1 | |
| SCHEMBL583953 | 0.76 | STAT3 (0.42) | STAT3TSHRMAPK1ALDH1A1TOP1 | |
| SCHEMBL2847619 | 0.76 | STAT3 (0.42) | STAT3ALDH1A1TDP1KDM4EHPGD | |
| SCHEMBL2841900 | 0.76 | STAT3 (0.42) | STAT3ALDH1A1TDP1KDM4EHPGD | |
| SCHEMBL2845727 | 0.76 | STAT3 (0.42) | STAT3ALDH1A1TDP1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | STAT3 4566/4885TSHR 2013/4885MAPK1 2698/4885 |
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | STAT3 4545/4885TSHR 1098/4885MAPK1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.